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Abstract
Intrahepatic cholestasis of pregnancy (ICP) is a cholestatic disorder characterized by (i) pruritus
with onset in the second or third trimester of pregnancy, (ii) elevated serum aminotransferases and
bile acid levels, and (iii) spontaneous relief of signs and symptoms within two to three weeks after
delivery. ICP is observed in 0.4–1% of pregnancies in most areas of Central and Western Europe
and North America, while in Chile and Bolivia as well as Scandinavia and the Baltic states roughly
5–15% and 1–2%, respectively, of pregnancies are associated with ICP. Genetic and hormonal
factors, but also environmental factors may contribute to the pathogenesis of ICP. Intrahepatic
cholestasis of pregnancy increases the risk of preterm delivery (19–60%), meconium staining of
amniotic fluid (27%), fetal bradycardia (14%), fetal distress (22–41%), and fetal loss (0.4–4.1%),
particularly when associated with fasting serum bile acid levels > 40 μmol/L. The hydrophilic bile
acid ursodeoxycholic acid (10–20 mg/kg/d) is today regarded as the first line treatment for
intrahepatic cholestasis of pregnancy. Delivery has been recommended in the 38th week when lung
maturity has been established.
Disease name and synonyms
Intrahepatic cholestasis of pregnancy
Obstetric cholestasis Recurrent jaundice of pregnancy
Pruritus gravidarum
Icterus gravidarum
Idiopathic jaundice of pregnancy
Definition
Intrahepatic cholestasis of pregnancy (ICP) is a cholestatic
disorder characterized by pruritus, elevated serum ami-
notransferases and bile acid levels with onset in the sec-
ond or third trimester of pregnancy, and spontaneous
relief of signs and symptoms within two to three weeks
after delivery [1,2].
In the first description of ICP in 1883, Ahlfeld described
maternal pruritus and jaundice in the last trimester of
pregnancy disappearing after delivery [3].
Epidemiology
ICP has been observed in almost all ethnic groups, but
there is relevant geographical variation in the incidence of
ICP [1,4]. The incidence of ICP was highest in Bolivia and
Chile several decades ago (up to 14% of all pregnancies
before 1975), particularly among the Araucanos Indians
of Chile (27.6%) and the Aimara Indians of Bolivia
(13.8%) [5-8], but has considerably decreased in these
countries more recently to less than 2% of all births today
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to 2% of all pregnancies, while in other regions of Europe,
Asia, North America and Australia the reported incidence
is less than 1% [1,7,9]. While the incidence has recently
decreased in the high-incidence regions, it increased in
low-incidence areas, possibly reflecting the raising aware-
ness of the disease [4,7]. ICP is more common in the win-
ter months in Chile and Scandinavia [10,11], and in twin
and multiple pregnancies [12].
Clinical manifestations and biochemical tests
Pruritus is the primary clinical symptom of ICP. Pruritus
may be mild and tolerable for some patients, but may also
be very severe and disabling. It may considerably impair
the patient's quality of life causing sleep deprivation, psy-
chological suffering and even suicidal thoughts. Pruritus
is most severe in the evening, with a predilection for the
palms of the hands and soles of the feet, and is not asso-
ciated with any specific skin lesions. It usually presents in
the third trimester, after 30 weeks of gestation, but rare
cases developing as early as 6 to 10 weeks have been
described [9,13,14]. Mild jaundice with serum levels of
conjugated bilirubin only moderately elevated occurs in
10 to 15% of cases [9,15]. Jaundice typically develops 1–
4 weeks after the onset of pruritus, but occasionally can be
the initial symptom [16,17]. Subclinical steatorrhea may
be seen along with fat malabsorption, which may lead to
vitamin K deficiency resulting in a prolonged pro-
thrombin time and postpartum hemorrhage [18,19]. The
incidence of gallstone formation and cholecystitis (rate
ratio 3.7) is higher in women with a history of ICP (as well
as in their first degree relatives) than in the normal popu-
lation [20]. Abdominal pain, malaise and other constitu-
tional symptoms are uncommon.
The main biochemical alterations are elevations of serum
bile acids and aminotransferase activities [21]. Serum
total bile acid levels may increase 10–100 times above the
normal range and higher fetal complications rates were
observed with maternal fasting bile acid levels exceeding
40 μmol/L [22-25]. In ICP, cholic acid is raised more than
chenodeoxcholic acid with an increase in the usual molar
ratio of serum cholic to chenochenodeoxcholic acid,
whereas the ratio of glycine- to taurine-conjugated bile
acids decreases [13,26-28]. Of interest, a subgroup of
asymptomatic healthy pregnant women with total serum
bile acids above the upper normal limit of 11 μM in late
gestation and normal serum liver tests has recently been
defined as asymptomatic hypercholanemia of pregnancy
(AHP) [29,30]. The serum bile acid composition of
women with ICP revealed a shift towards a more hydro-
phobic pattern with higher levels of lithocholic acid and
unconjugated serum bile acids, suggesting that these alter-
ations could be additional useful parameters in the differ-
ential diagnosis of ICP and AHP [30]. Serum
aminotransferases are also elevated 2–10-fold above nor-
mal in 20–60% of patients with pruritus, and may exceed
1000 U/L in exceptional cases [1,9,10,16,31]. Serum ami-
notransferases may allow better to follow patients with
ICP after start of UDCA treatment than total fasting serum
bile acid levels which initially increase due to an increase
in ursodeoxycholic acid (UDCA) serum levels. Serum con-
centrations of gamma glutamyl transpeptidase are normal
or modestly elevated in half of the patients, reaching up to
four times the upper normal limits [9,13]. Serum levels of
alkaline phosphatase may rise up to 7–10 times normal,
but are difficult to interpret due to elevation of the pla-
centa isoenzyme [32].
Maternal outcome
Maternal prognosis is good and symptoms resolve rapidly
after delivery, accompanied by normalization of serum
liver tests [28]. Persistent abnormalities should prompt
reconsideration of other underlying chronic liver diseases
like primary biliary cirrhosis, primary sclerosing cholangi-
tis, or chronic hepatitis C which all may be associated with
development of pruritus during late pregnancy. ICP recurs
during subsequent pregnancies in 45–70% with varying
severity of recurrent episodes [9].
Fetal outcome
ICP increases the risk of preterm delivery (up to 19–60%)
[9,33,34], meconium staining of amniotic fluid (up to
27%) [35], fetal bradycardia (up to 14%) [35], fetal dis-
tress (up to 22–41%) [11,33,36], and fetal loss (up to 0.4–
4.1%) [33,37,38], particularly when associated with fast-
ing serum bile acid levels > 40 μmol/L [25]. Fasting serum
bile acid levels and severity of pruritus at diagnosis were
independent predictors of preterm delivery in a recent
analysis (Kondrackiene et al., submitted). Interestingly,
most recent data show a marked decrease in fetal compli-
cations [25,39-42] possibly in part due to greater aware-
ness for the disease, closer follow-up and experienced
management in specialized centers. Autopsies of the still-
borns show signs of acute anoxia with serosal and pulmo-
nary petechial bleeding without intrauterine growth
retardation [18,35,43]. The pathogenesis of the fetal com-
plications is still poorly understood, although a role for
bile acids or toxic metabolites of bile acids has been sug-
gested [4]. Bile acids were shown to induce contraction of
the chorionic veins of the placenta, and myometrial sensi-
tivity of healthy women to oxytocin was increased after
incubation with cholic acid [44,45]. The infusion of
cholic acid in fetal lambs stimulates colonic motility
increasing the incidence of meconium passage [46]. In a
prospective study of ICP in patients with bile acid levels >
40 μmol/L the frequency of meconium passage was 44%
compared to 22% in a group with only mild ICP [25].Page 2 of 6
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2007, 2:26 http://www.OJRD.com/content/2/1/26Etiology and pathogenesis
The etiology of ICP is not completely understood and is
still under discussion. Genetic and hormonal factors, but
also environmental factors may contribute to the patho-
genesis of ICP [1]. Familial clustering, ethnic and geo-
graphic variation, and the high rate of reoccurrence in
subsequent pregnancies support a genetic predisposition
for ICP [1,47]. Mutations in the hepatocellular phosphol-
ipid transporter, ABCB4 (MDR3), that mediates secretion
of the major human phospholipid, phosphatidylcholine
(lecithine) into bile, have been estimated to account for
up to 15% of all ICP cases [21,48,49]. Available molecular
genetic analysis suggests that other major ABC transport-
ers of liver cells, the bile salt export pump (BSEP),
ABCB11, and the aminophospholipid transporter (FIC1),
ATP8B1, are less likely to be implicated in the pathogene-
sis of ICP [21,50-52].
Clinical evidence supports an etiologic role for estrogens
in the initiation of ICP [1,53,54]. ICP most commonly
occurs in the last trimester, when estrogen levels reach
their maximum. ICP has been associated with twin and
triplet pregnancies with higher estrogen levels than single
gestations. Finally, estrogen oral contraceptive use among
women with a personal or family history of ICP could
result in clinical features of ICP particularly when former
high-dose preparations were used [1,4,32]. Progesterone
and associated metabolites may also be involved in the
pathogenesis of ICP. Patients with ICP have significantly
increased plasma levels of mono- or disulfated progester-
one metabolites and an increased ratio of 3α-hydroxy-
lated steroids to 3β-hydroylated steroids [47,55,56]. Some
estrogens, in particular 17β-D-glucuronide, and sulfated
progesterone metabolites have been shown to cause
cholestasis [57], but the molecular mechanism is still
under discussion. Impairment of the function of major
hepatocellular ABC transporters like the bile salt export
pump (BSEP), ABCB11, or the phospholipid transporter,
ABCB4 (MDR3), by high levels of estrogen glucuronides
and progesterone, respectively, at the posttranscriptional
level has been demonstrated in vitro [58-60]. In addition,
estrogens impaired basolateral as well as canalicular bile
acid transporter expression of liver cells in vitro by tran-
scriptional mechanisms [61].
Thus, mutations in genes encoding hepatobiliary trans-
port proteins as well as abnormal metabolites impairing
hepatobiliary carriers may be involved in the pathogene-
sis of ICP.
The seasonal variation, the incomplete recurrence in sub-
sequent pregnancies, as well as the decrease in the preva-
lence of ICP in high-incidence regions in association with
improved nutritional supply suggest that exogenous fac-
tors such as nutritional factors like selenium deficiency
may contribute to ICP [62,63].
Diagnosis
The diagnosis of ICP is based on (i) pruritus of cholestasis,
(ii) elevated fasting serum bile acids > 10 μmol/L (and ele-
vated serum transaminases), (iii) spontaneous relief of
signs and symptoms within two to three weeks after deliv-
ery and (iv) absence of other diseases that cause pruritus
and jaundice. Liver biopsy is not necessary for the diagno-
sis and histopathology is not diagnostic, showing centri-
lobular cholestasis without inflammation and bile plugs
in hepatocytes and caniculi without bile duct dilatation or
injury [16,64].
Differential diagnosis
A number of other disorders may erroneously be inter-
preted as ICP during pregnancy, making exclusion of dis-
eases associated with pruritus without cholestasis or with
pruritus with cholestasis important. The differential diag-
nosis of ICP with pruritus (and elevation of serum bile
acid levels) only includes skin diseases and specific derm-
atoses of pregnancy, allergic reactions, renal pruritus and
hematological disorders such as Hodgkin's disease and
polycythemia rubra vera. ICP with elevation of serum liver
tests should be distinguished in the late 1st trimester from
hyperemesis gravidarum, in the 3rd trimester from acute
fatty liver of pregnancy, HELLP (a syndrome characterized
byHemolysis, Elevated Liver enzyme levels and a Low
Platelet count), pre-eclampsia, eclampsia, and in all tri-
mesters from viral hepatitis, alcoholic hepatitis, drug-
induced hepatitis, biliary obstruction, hyperbilirubinemic




The primary objective of pharmacologic treatment in ICP
is to alleviate maternal symptoms and improve fetal out-
come. Antihistamines, benzodiazepines, phenobarbital,
opioid antagonists, dexamethasone, epomediol, S-adeno-
syl-L-methionine and cholestyramine have been used but
not introduced into clinical practice because of limited
efficacy and/or tolerability [1,32,39].
Currently, the hydrophilic bile acid ursodeoxycholic acid
(UDCA) is the most effective treatment for ICP. In an
open, randomized, parallel group study, 84 symptomatic
patients with ICP were randomized to either UDCA, 8–10
mg/kg body weight per day, or cholestyramine, 8 g per
day, for 14 days. Relief of pruritus was significantly more
pronounced in the UDCA group and serum alanine and
aspartate aminotransferase activities and endogenous
serum bile acid levels were more effectively lowered after
UDCA therapy. In addition, delivery occurred closer toPage 3 of 6
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ble-blind, placebo-controlled trial comparing UDCA (1 g
per day for three weeks) and dexamethasone (12 mg per
day for one week) in 130 women with ICP demonstrated
significant improvement of serum alanine aminotrans-
ferase and bilirubin levels irrespective of disease severity
in the UDCA group only and significant improvement of
pruritus in the subgroup of women in the UDCA group
with bile acid levels = 40 μmol/L at study entrance. In con-
trast, dexamethasone did not alleviate pruritus, and serum
bile acids and bilirubin were less effectively reduced com-
pared to the UDCA group. However, no differences in
fetal complications were detected, possibly due to the fact
that fetal complications were less frequently observed in
the whole study population than in previous studies [39].
In a retrospective, non-randomized analysis of a 12-year
observation period, 32 patients with ICP were treated with
UDCA (15 mg/kg/day) for three or more weeks before
delivery and compared with 16 historical untreated con-
trols with similar clinical and biochemical characteristics.
UDCA treatment significantly improved pruritus intensity
and some biochemical markers of ICP and resulted in a
higher proportion of deliveries at term with a higher birth
weight compared with historical controls [21,41]. A
recent randomized prospective comparative study of
UDCA (750 mg per day) and S-adenosyl-L-methionine
(1000 mg per day intravenously) of 78 patients with ICP
suggested that both regimens improved pruritus, but the
combined therapy had no additive effect on pruritus as
compared to UDCA monotherapy [42]. UDCA seems to
be well tolerated by pregnant women and no adverse
effects in mothers or newborns have been observed [39-
42]. The mechanisms underlying the beneficial effects of
UDCA in ICP are not entirely clear. UDCA has been
shown to improve impaired hepatocellular secretion by
mainly posttranscriptional stimulation of canalicular
expression of key transport proteins like the conjugate
export pump, MRP2 (ABCC2), or the bile salt export
pump, BSEP (ABCB11) [65,66]. In particular, targeting
and insertion of these transporter proteins into the canal-
icular membrane by UDCA conjugates has been demon-
strated in experimental models of cholestasis, which led
to enhanced elimination of bile acid metabolites and
other organic anions as well as steroid mono- and disul-
fates [65,66]. This mechanism might be crucial for the
understanding of the beneficial effect of UDCA in ICP.
In addition to effects of UDCA on the maternal liver,
UDCA restores the impaired maternal-placental bile acid
transport across the trophoblast. This could be mediated
by enhanced expression of plasma membrane transport-
ers involved in the excretory role of the placenta and
would prevent structural alterations of the trophoblast
induced by maternal cholestasis [15,21].
Delivery
Since conventional antepartum testing does not reliably
predict fetal mortality and induction of labor in the 38th
week of gestation has been observed to reduce fetal risk,
delivery has been recommended in the 37th to 38th week
in ICP. In most severe cases (before the era of UDCA treat-
ment), delivery has been initiated even at 36 weeks gesta-
tion as soon as lung maturity had been established
[28,34,67]. As clearly stated by the UK Guideline for Obstet-
ric Cholestasis 2006, "there are insufficient data to support
or refute the popular practice of 'early' (37 weeks of gesta-
tion) induction of labour aimed at reducing late stillbirth.
The timing and risks of delivery should, therefore, be dis-
cussed on an individual basis."
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